REST Inactivation and Coexpression of ASCL1 and POU3F4 Are Necessary for the Complete Transformation of RB1/TP53-Inactivated Lung Adenocarcinoma into Neuroendocrine Carcinoma-Reference-Cited by-同舟云学术

REST Inactivation and Coexpression of ASCL1 and POU3F4 Are Necessary for the Complete Transformation of RB1/TP53-Inactivated Lung Adenocarcinoma into Neuroendocrine Carcinoma

Published:2022-06 Issue:6 Volume:192 Page:847-861
ISSN:0002-9440
Container-title:The American Journal of Pathology
language:en
Short-container-title:The American Journal of Pathology

Author:

Masawa Meitetsu,Sato-Yazawa Hanako,Kashiwagi Korehito,Ishii Jun,Miyata-Hiramatsu Chie,Iwamoto Masami,Kohno Kakeru,Miyazawa Tadasuke,Onozaki Masato,Noda Shuhei,Shimizu Yasuo,Niho Seiji,Yazawa Takuya

Funder

Japan Society for the Promotion of Science

Publisher

Elsevier BV

Subject

Pathology and Forensic Medicine

Reference44 articles.

1. Molecular biology of lung cancer: diagnosis and management of lung cancer, 3rd edition: American College of Chest Physicians evidence-based clinical practice guidelines;Nana-Sinkam;Chest,2013

2. The WHO Classification of Tumours Editorial Board (Ed): Lung neuroendocrine neoplasms. Thoracic Tumours. WHO Classification of Tumours. ed 5. Lyon,2020

3. Class III/IV POU transcription factors expressed in small cell lung cancer cells are involved in proneural/neuroendocrine differentiation;Ishii;Pathol Int,2014

4. Small cell lung cancer, an epithelial to mesenchymal transition (EMT)-like cancer: significance of inactive Notch signaling and expression of achaete-scute complex homologue 1;Ito;Hum Cell,2017

5. Neural lineage-specific homeoprotein BRN2 is directly involved in TTF1 expression in small-cell lung cancer;Sakaeda;Lab Invest,2013

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A novel transient receptor potential C3/C6 selective activator induces the cellular uptake of antisense oligonucleotides;Nucleic Acids Research;2024-04-16

2. Histological transformation into SCLC: An important resistance mechanism of NSCLC upon immunotherapy;Frontiers in Immunology;2023-10-30

3. Etoposide/platinum plus anlotinib for patients with transformed small-cell lung cancer from EGFR-mutant lung adenocarcinoma after EGFR-TKI resistance: a retrospective and observational study;Frontiers in Oncology;2023-06-09